Hpv-related Carcinoma
📧 Sign up to get email alerts when something new happens for Hpv-related Carcinoma.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS trial_result · 2026-04-23Clinical Trial Update: PRGN-2009 in Combination With Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer [Phase 2]
Phase 2 trial updating PRGN-2009 in combination with pembrolizumab for recurrent or metastatic cervical cancer is currently recruiting.
-
CLINICAL_TRIALS research · 2026-02-09Clinical Trial Update: Biomarker Approach to Screening for the Early Detection of HPV-related Oropharyngeal Cancer (BASH OPC)
This clinical trial update describes a biomarker-based screening approach for the early detection of HPV-related oropharyngeal cancer and is…
-
CLINICAL_TRIALS trial_result · 2026-01-16Clinical Trial Update: A Phase III Clinical Trial of a 11-valent Recombinant Human Papillomavirus Vaccine (Hansenulapolymorpha) in Chinese Women Aged 9-45 Years [Phase 3]
Phase III clinical trial in Chinese women aged 9-45 evaluating an 11-valent recombinant HPV vaccine; the study is currently in recruitment.
-
CLINICAL_TRIALS trial_result · 2025-01-06Clinical Trial Update: A Phase I Clinical Trial to Evaluate the Safety of 15-valent HPV Vaccine in Healthy Chinese People Aged 18-45 Years [Phase 1]
Phase I clinical trial evaluating the safety of a 15-valent HPV vaccine in healthy Chinese adults aged 18-45. The study is currently active …
-
CLINICAL_TRIALS trial_result · 2023-09-18Clinical Trial Update: A Study to Evaluate the Efficacy, Safety, and Immunogenicity of SCT1000 in Healthy Women Aged 18-45 Years [Phase 3]
Phase 3 study evaluating SCT1000 for efficacy, safety, and immunogenicity in healthy women; currently active but not recruiting.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2023-03-03Clinical Trial Update: A Phase I/II Study of Regorafenib Plus Avelumab in Solid Tumors [Phase 1, Phase 2]
A Phase I/II study investigating regorafenib in combination with avelumab in various solid tumors, spanning Phase 1 and Phase 2 cohorts.